has developed an automated personal hemodialysis system for patient-performed hemodialysis in alternative care settings such as the patient's home.
American Medical Systems Holdings, Inc.
acquired from Pfizer Inc., manufactures and markets devices to surgically treat incontinence and impotence.
(ticker: AMMD)
reprocesses medical devices for re-use by medical facilities.
(formed by the merger of Alliance Medical Corporation and Vangaurd Medical Concepts; acquired by Stryker Corporation, ticker: SYK)
is marketing and developing systems to inactivate viruses, bacteria and other pathogens in blood components for transfusion. The company also is focused on developing new vaccine technologies.
(ticker: CERS)
developed therapeutic antibodies and targeted oncologics to treat cancer.
(ticker was CLTR; acquired by Corixa Corporation ticker: CRXA, and subsequently acquired by GlaxoSmithKline plc ticker: GSK)
marketed a minimally invasive diagnostic system for mapping arrhythmias, potentially fatal or life debilitating heart rhythms.
(ticker was ECSI; acquired by St. Jude Medical, Inc. ticker: STJ)
developed devices for the treatment of atrial fibrillation.
(acquired by St. Jude Medical, Inc. ticker: STJ)
Image-Guided Neurologics, Inc.
developed and marketed devices to improve the accuracy of, and reduce the time required for, image-guided neurosurgery.
(acquired by Medtronic, Inc. ticker MDT)
is a licensing-focused, drug development company currently marketing Angiomax™, a novel anti-coagulant.
(ticker: MDCO)
utilized proprietary "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds. MACUGEN®, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.
(ticker was NXGN; merged with Vestar, Inc. to become NeXstar, Inc. with ticker NXTR and subsequently acquired by Gilead Sciences, Inc. ticker: GILD)
was a leading technology developer in the fields of glycobiology and proteomics. Utilizing its technology, the company developed a lead pharmaceutical product Zavesca®, that was approved by the European Commission, and established proteomics collaborations with several multi-national pharmaceutical companies.
(ticker was OGSI; acquired by Celltech Group plc ticker: CLL and subsequently acquired by UCB S.A. ticker: UCB.BR)
developed novel technologies for the production of human proteins and for gene therapy systems. Products developed with these technologies include Replagal™, a drug approved for the treatment of Fabry Disease and ElapraseT, a product awaiting approval for Hunter syndrome.
(ticker was TKTX; acquired by Shire Pharmaceuticals Group PLC ticker: SHPGY)
developed and marketed analytical testing systems that enabled more accurate selection of pharmaceutical regimes for patients with HIV.
(ticker was VGIN; acquired by Bayer Corporation ticker: BAY)
manufactures and markets a full line of orthopedic implants with leading shares of the small joint replacement and biologically active bone void filler markets.
(ticker: WMGI)
was acquired from Bristol-Myers Squibb Company, and manufactured and marketed products for the treatment of ear, nose and throat diseases.
(ticker was XOMD; acquired by Medtronic, Inc. ticker: MDT)